#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mycobacterium abscessus infection Human papilloma virus immunisation Waldenstrom's macroglobulinaemia refractory Germ cell cancer Acute myeloid leukaemia (in remission) Hereditary ataxia Parkinson's disease Ewing's sarcoma metastatic Langerhans' cell histiocytosis Osteogenesis imperfecta Osteomyelitis Endocrine ophthalmopathy C3 glomerulopathy Liposarcoma metastatic Splenic marginal zone lymphoma More trials…

    Learn about Rare Diseases

    Soft tissue sarcoma – Diagnostics Systemic mastocytosis – Trials in Disease Osteosarcoma – Diagnostics Congenital generalised lipodystrophy – Diagnostics Hairy cell leukaemia – Trials in Disease Uterine leiomyosarcoma – Trials in Disease Gaucher’s disease type I – Treatment Activated PI3 kinase delta syndrome – Life with Disease Mantle cell lymphoma refractory – Diagnostics Fabry’s disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    TUVATEXIB Piperacillin Monohydrate APAZUNERSEN Xenon (129Xe) Ivabradine Hydrochloride Ganciclovir Sodium Gtaexs617 CYCLIZINE HYDROCHLORIDE Pilocarpine Hydrochloride Rituximab Desoximetasone ATUMELNANT Terbinafine Hydrochloride Dexchlorpheniramine Maleate Myrrh Vemircopan Gs-5718-03 RO7284755 Cdr132L Atl001 More therapies…

    Learn about Your Condition

    Extraskeletal ossification Hip fracture Endocrine ophthalmopathy Leukocyte adhesion deficiency Pseudomonas infection Adrenal insufficiency Malabsorption Cardiac valve disease Postprandial hypoglycaemia COVID-19 Coronary artery dissection Bronchiolitis Diabetic retinopathy Uveal melanoma Essential hypertension More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Virus Diseases

  • Study on Switching from Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Patients with Good Control and Neuropsychiatric Concerns

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HIV infection
    Investigated Drugs:
    • Dolutegravir Sodium
    • Lamivudine
    • Bictegravir
    Spain

  • Study on the Safety and Effectiveness of Nirmatrelvir and Ritonavir for Nonhospitalized Children with COVID-19 at Risk of Severe Illness

    Not recruiting

    4 1 1
    Investigated Diseases:
    • COVID-19
    Investigated Drugs:
    • Ritonavir
    • Nirmatrelvir
    Bulgaria Hungary

  • Study on the Effects of Vidofludimus Calcium for Patients with Post-COVID Syndrome

    Not recruiting

    2 1
    Investigated Diseases:
    • Post-acute COVID-19 syndrome
    Investigated Drugs:
    • Vidofludimus Calcium
    Germany

  • Study on the Safety and Immune Response of RSVPreF3 Vaccine for Respiratory Syncytial Virus in Adults Aged 60 and Above

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
    Finland Germany

  • Study on Pritelivir for Treating Acyclovir-Resistant Herpes Simplex Virus in Immunocompromised Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Herpes simplex
    Investigated Drugs:
    • Foscarnet Sodium Hexahydrate
    • Pritelivir
    • Anhydrous Cidofovir
    Belgium France Germany Greece Italy

  • Study of nirmatrelvir and ritonavir (Paxlovid) for prevention of long COVID-19 in patients with acute COVID-19 infection in Norway

    Not recruiting

    3 1 1
    Investigated Diseases:
    • COVID-19
    Investigated Drugs:
    • Ritonavir
    • Nirmatrelvir
    Norway
Previous Page
1 … 42 43 44 45 46 … 51
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!